Cooperative Agreement AIDOAAF1600090

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $354,570 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Case Western Reserve University to develop a cost-effective, user-friendly point-of-care diagnostic tool for detecting HIV and hepatitis B virus (HBV) co-infection. The project aims to create a microchip platform utilizing color-encoded beads coated with antibodies to capture vital biomarkers, including HIV-1 RNA, HBV...

This $776,341 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a microfluidic cartridge, molecular biology method, biosensor, and detection instrument that can simultaneously detect HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) viral loads from a minimal volume of whole blood. The goal is to create a robust, cost-effective point-of-care (POC) diagnostic test that can...

This Project Grant award of $293,142 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) aims to develop a rapid diagnostic test (RDT) in a lateral flow assay (LFA) format for detecting Babesia microti infection. B. microti is a parasite transmitted by the same tick that causes Lyme disease and can lead to severe illness if not rapidly diagnosed. The goal is to create a test suitable for use...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $304,966 to Kompass Diagnostics Inc. aims to develop a portable, cost-effective diagnostic device that can rapidly detect multiple blood-based biomarkers. The key focus is on enabling rapid, quantitative measurement of reproductive hormones to support time-sensitive clinical decisions in fertility treatments. The research objectives include developing an integrated...

This Project Grant award from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283) provides $1,047,807 to Nanohmics Inc., a small technology company in Austin, Texas, to develop a Lateral Flow-Electrochemiluminescent (LF-ECL) test strip and portable reader system for ultrasensitive detection of foodborne pathogens. The award period runs from Sep 30, 2025 to Sep 29, 2027. The CDC program supports research, surveillance, and technical...

This $960,000 National Science Foundation project grant supports the development of a multiplexed plasmon-enhanced lateral flow assay for point-of-care detection of SARS-CoV-2 RNA and antigens. Funded under the NSF Engineering program (CFDA 47.041), the grantee, Washington University, will design, validate and build a novel diagnostic platform with sensitivity exceeding standard laboratory tests. Key deliverables include an ultrasensitive multiplexed lateral flow assay for simultaneous...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $885,006 to Brigham & Women's Hospital Inc. to develop a smartphone-based point-of-care diagnostic system for detecting Alzheimer's disease-related biomarkers in blood plasma. The system will utilize microfluidics, nanotechnology, optical sensing, and deep learning to measure amyloid-beta, phosphorylated tau, and neurofilament light chain within 30 minutes, with the goal of creating an...

This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...